Antigua and Barbuda Will Market Cuban Heberprot-P

Featured Antigua and Barbuda Will Market Cuban Heberprot-P

Havana, Jul 6 (Prensa Latina) Representatives of Antigua and Barbuda and Cuba signed a memorandum of understanding that will allow the marketing of the Cuban drug Heberprot-P for the treatment of diabetic foot, reported official sources.

The Antiguan Minister of Health, Welfare and Environment, Molwyn Joseph, and the General Director of the Center for Genetic Engineering and Biotechnology (CIGB), Eulogio Pimentel, signed the document as part of a working visit made by the Caribbean official to this capital.

Joseph and his team met with Cuban Minister of Health, Roberto Morales, senior official of the visit's coordinating body, and who was also present in the memorandum's signature.

Cuba and Antigua and Barbuda maintain a close collaboration in health matters and as a result a high number of students from that Caribbean country have graduated from the Latin American School of Medical Sciences (ELAM), the source reported.

At the request of the agreements with the Caribbean Community, Cuba maintains its offer of scholarships for which Antiguan students annually enter the ELAM. At the same time, Cuban collaborators have been serving in that country for almost two decades.

Leave a comment